[Skip to Navigation]
Views 699
Citations 0
Clinical Trials Update
September 22/29, 2015

Antisense Inhibitor Lowers High Triglycerides

JAMA. 2015;314(12):1217. doi:10.1001/jama.2015.11081

A recent phase 2 randomized controlled trial reported that short-term treatment with ISIS 304801, a second-generation antisense inhibitor of apolipoprotein C-III (APOC3) synthesis, reduced triglyceride levels in patients with severe or uncontrolled hypertriglyceridemia. High triglyceride levels can cause insulin resistance, metabolic syndrome, diabetes, cardiovascular disease. Reducing APOC3, a key regulator of plasma triglyceride levels, may be cardioprotective and lower the risk of pancreatitis in patients with very high triglyceride levels, according to the investigators (Gaudet D et al. N Engl J Med. 2015;373[5]:438-447).